Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

US10537573B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Brian D. KLEIN · Potomac, US
• Hilde Lavreysen · Lommel, BE
• Stefan Maria Christiaan Pype · Boechout, BE
• Roy E. Twyman · Doylestown, US
• Nancy Eulalie Sylvain Van Osselaer · Lier, BE
• H. Steven WHITE · Seattle, US
• Marc André Ceusters · Diest, BE
• Jose Maria Cid-Nunez · Toledo, ES
• Andrés Avelino Trabanco-Suárez · Toledo, ES
• Roger F. Bone · Bound Brook, US

Key dates

• Filing date: Jan 20, 2015
• Grant date: Jan 21, 2020
• Expiry date: Jan 20, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.